Regional cerebral blood flow and metabolic rate in persistent lyme encephalopathy

Archives of General Psychiatry

Volumn 66, Issue 5, 2009, Pages 554-563

  Fallon, Brian A ^a,b   Lipkin, Richard B ^c   Corbera, Kathy M ^a,b   Yu, Shan ^a,b   Nobler, Mitchell S ^b,d   Keilp, John G ^a,b   Petkova, Eva ^a,b   Lisanby, Sarah H ^a,b   Moeller, James R ^a,b   Slavov, Iordan ^a,b   Heertum, Ronald Van ^a   Mensh, Brett D ^a,b   Sackeim, Harold A ^a,b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; ANTIINFECTIVE AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; OXYGEN;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; LYME DISEASE; MALE; MEMORY DISORDER; METABOLIC RATE; BLOOD FLOW; BRAIN; CASE CONTROL STUDY; CHRONIC DISEASE; ENERGY METABOLISM; HEMISPHERIC DOMINANCE; IMAGE PROCESSING; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REFERENCE VALUE; VASCULARIZATION;

ADULT; ANTI-BACTERIAL AGENTS; BRAIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOMINANCE, CEREBRAL; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYME NEUROBORRELIOSIS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; OXYGEN CONSUMPTION; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES; REGIONAL BLOOD FLOW;

EID: 65549118629     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.29     Document Type: Article

References (42)

1. Shadick NA, Phillips CB, Sangha O, Logigian EL, Kaplan RF, WrightEA, Fossel AH, Fossel K, Berardi V, Lew RA, Liang MH. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med. 1999;131(12): 919-926.
2. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol. 2005;34(6):1340-1345.
3. Cameron D, Gaito A, Harris N, Bach G, Bellovin S, Bock K, Bock S, Burrascano J, Dickey C, Horowitz R, Phillips S, Meer-Scherrer L, Raxlen B, SherrV, Smith H, Smith P, Stricker R; ILADS Working Group. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther. 2004;2(1)(suppl):S1-S13.
4. Feder HM Jr, Johnson B, O'Connell S, Shapiro ED, Steere AC, Wormser GP, Agger WA, Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, DraperT, McSweegan E, Halperin JJ, KlempnerMS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP Jr, Sood S, Weinstein A, Wong SJ,Zemel L; Ad Hoc International Lyme Disease Group. A critical appraisal of "chronic Lyme disease" [correction published in NEngl JMed. 2008;358(10):1084]. NEngl JMed. 2007;357(14):1422-1430.
5. Alaedini A, Latov N. Antibodies against OspAepitopes of Borrelia burgdorferi crossreact with neural tissue. JNeuroimmunol. 2005;159(1-2):192-195.
6. Halperin JJ, Pass HL, Anand AK, Luft BJ, Volkman DJ, Dattwyler RJ. Nervous system abnormalities in Lyme disease. Ann N YAcadSci. 1988;539:24-34.
7. Kriiger H, Heim E, Schuknecht B, Scholz S. Acute and chronic neuroborreliosis with and without CNS involvement: a clinical, MRI, and HLA study of 27 cases. J Neurol. 1991;238(5):271-280.
8. Halperin JJ, Luft BJ, Anand AK, Roque CT, Alvarez O, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis: central nervous system manifestations. Neurology. 1989; 39(6):753-759.
9. Aalto A, Sjowall J, Davidsson L, Forsberg P, Smedby O. Brain magnetic resonance imaging does not contribute to the diagnosis of chronic neuroborreliosis. Acta Radiol. 2007;48(7):755-762.
10. Fallon BA, Das S, Plutchok JJ, Tager F, Liegner K, Van Heertum R. Functional brain imaging and neuropsychological testing in Lyme disease. Clin InfectDis. 1997;25(suppl 1):S57-S63.
11. Logigian EL, Johnson KA, KijewskiMF, Kaplan RF, Becker JA, Jones KJ,GaradaBM, Holman BL, Steere AC. Reversible cerebral hypoperfusion in Lyme encephalopathy. Neurology. 1997;49(6):1661-1670.
12. Fallon BA, Keilp J, Prohovnik I, Heertum RV, Mann JJ. Regional cerebral blood flowand cognitive deficits in chronic lyme disease. J Neuropsychiatry Clin Neurosci. 2003;15(3):326-332.
13. Newberg A, Hassan A, Alavi A. Cerebral metabolic changes associated with Lyme disease. NuclMedCommun. 2002;23(8):773-777.
14. Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995;44 (31):590-591.
15. Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
16. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R: SCID-P - Patient Edition. Arlington, VA: American Psychiatric Press, Inc; 1990.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, VA: American Psychiatric Publishing Inc; 2000.
18. Keilp JG, Sackeim HA, Mann JJ. Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res. 2005;135(3):191-201.
19. Sackeim HA, Keilp JG, Rush AJ, George MS, Marangell LB, Dormer JS, Burt T, Lisanby SH, Husain M, Cullum CM, Oliver N,Zboyan H. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry NeuropsycholBehavNeurol. 2001;14(1):53-56.
20. Beck A, Steer RA, Brown GA. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
21. Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12 (6):371-379.
22. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. BrJPsychiatry. 1976;1:280-289.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123.
24. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30(2):191-197.
25. Ware JE, Kosinski M. Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute; 1994.
26. Davis PH, Dambrosia JM, Schoenberg BS, Schoenberg DG, Pritchard DA, Lilenfeld AM, Whisnanat JP. Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann Neurol. 1987;22(3):319-327.
27. Herscovitch P. Cerebral blood flowand metabolism measured with oxygen-15 radiotracers. J Neuropsychiatry Clin Neurosci. 1989;1(1):S19-S29.
28. Vorstrup S. Tomographic cerebral blood flow measurements in patients with ischemic cerebrovascular disease and evaluation of the vasodilatory capacity by the acetazolamide test. Acta Neurol Scand Suppl. 1988;114:1-48.
29. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE.Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro- 2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6(5):371-388.
30. Turkington TG, Hoffman J, Jaszczak RJ, MacFall JR, Harris CC, Kilts CD, Pelizzari CA, Coleman RE. Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces. JComputAssist Tomogr. 1995; 19(1):117-124.
31. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum BrainMapp. 2004;2:189-210.
32. Kao CH, Ho YJ, Lan JL, Changlai SP, Liao KK, Chieng PU. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus in patients with normal brain magnetic resonance imaging findings. Arthritis Rheum. 1999;42(1):61-68.
33. Warach S, Gur RC, Gur RE, Skolnick BE, Obrist WD, Reivich M. The reproducibility of the 133Xe inhalation technique in resting studies: task order and sex related effects in healthy young adults. J Cereb Blood Flow Metab. 1987;7(6): 702-708.
34. Gur RC, Gur RE, Resnick SM, Skolnick BE, Alavi A, Reivich M. The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab. 1987;7(2):173-177.
35. Romi F, Krakenes J, Aarli JA, Tysnes OB. Neuroborreliosis with vasculitis causing stroke-like manifestations. Eur Neurol. 2004;51(1):49-50.
36. Brogan GX, Homan CS, Viccellio P. The enlarging clinical spectrum of Lyme disease: Lyme cerebral vasculitis, a new disease entity. Ann Emerg Med. 1990; 19(5):572-576.
37. Veenendaal-Hilbers JA, Perquin WV, Hoogland PH, Doornbos L. Basal meningovasculitis and occlusion of the basilar artery in two cases of Borrelia burgdorferi infection. Neurology. 1988;38(8):1317-1319.
38. Oksi J, Kalimo H, Marttila RJ, Marjamaki M, Sonninen P, Nikoskelainen J, Viljanen MK. Inflammatory brain changes in Lyme borreliosis: a report on three patients and review of literature. Brain. 1996;119(pt6):2143-2154.
39. Morgen K, Martin R, Stone RD, Grafman J, Kadom N, McFarland HF, Marques A. FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome. Neurology. 2001;57(11):1980-1985.
40. Sackeim HA, Prohovnik I, Moeller J, Brown RP, ApterS, PrudicJ, Devanand DP, Mukherjee S. Regional cerebral blood flow in mood disorders I: comparison of major depressives and normal controls at rest. Arch Gen Psychiatry. 1990; 47(1):60-70.
41. Mayberg HS. Frontal lobe dysfunction in secondary depression. J Neuropsy chiatry Clin Neuro sci. 1994;6(4):428-442.
42. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48 (8):813-829.